Will Clinuvel Pharmaceuticals Limited Go Down Anytime Soon?

 Will Clinuvel Pharmaceuticals Limited Go Down Anytime Soon?

The stock of Clinuvel Pharmaceuticals Limited (ASX:CUV) is a huge mover today! The stock increased 26.76% or $1.94 on October 28, hitting $9.19. About 30,888 shares traded hands or 31.79% up from the average. Clinuvel Pharmaceuticals Limited (ASX:CUV) has risen 123.60% since April 1, 2016 and is uptrending. It has outperformed by 118.89% the S&P500.
The move comes after 5 months positive chart setup for the $438.59M company. It was reported on Oct, 28 by Barchart.com. We have $21.87 PT which if reached, will make ASX:CUV worth $605.25M more.

More important recent Clinuvel Pharmaceuticals Limited (ASX:CUV) news were published by: Businesswire.com which released: “SurModics Signs License Agreement with Clinuvel Pharmaceuticals” on July 07, 2010, also Globenewswire.com published article titled: “Clinuvel to file new drug with FDA”, Seekingalpha.com published: “Scenesse Approval Increases Clinuvel’s Credibility” on October 24, 2014. More interesting news about Clinuvel Pharmaceuticals Limited (ASX:CUV) was released by: Fool.com.Au and their article: “Here’s why these 4 shares crashed on the market today” with publication date: March 07, 2016.

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical firm focused on developing drugs for the treatment of a range of severe skin disorders. The company has a market cap of $438.59 million. The Company’s focus is to develop and commercialize SCENESSE as a medicinal photoprotective solution for patients who are most severely affected by ambient light exposure and UV. It currently has negative earnings. The Company’s lead compound, SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the United States, Europe and Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment